Search

Your search keyword '"Salmon, Dominique"' showing total 4 results
Start Over Author "Salmon, Dominique" Journal antiviral therapy
4 results on '"Salmon, Dominique"'

1. Incidence, Medical and Socio-Behavioural Predictors of Psychiatric Events in An 11-Year Follow-Up of HIV-Infected Patients on Antiretroviral Therapy

Author

Protopopescu, Camelia, Raffi, François, Brunet-François, Cécile, Salmon, Dominique, Verdon, Renaud, Reboud, Philippe, Carrieri, Maria Patrizia, Leport, Catherine, Spire, Bruno, Michel, Laurent, Michelet, Christian, Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Maladies infectieuses et tropicales, Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), APROCO-COPILOTE (ANRS CO8) Study Group, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Aix Marseille Université ( AMU ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM - U912 INSERM - AMU - IRD ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Service des maladies infectieuses et tropicales, CHU Caen, Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), and Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA )

Subjects
Male, MESH: CD4 Lymphocyte Count, Epidemiology, HIV Infections, MESH : Viral Load, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Surveys and Questionnaires, Immunopathology, Hiv infected patients, Pharmacology (medical), Longitudinal Studies, MESH: Incidence, MESH: Treatment Outcome, MESH: Middle Aged, Depression, MESH: HIV, Incidence, MESH : HIV Protease Inhibitors, MESH: Follow-Up Studies, MESH: HIV Infections, MESH : Incidence, 3. Good health, Suicide, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Drug Therapy, Combination, Viral disease, Infection, 0305 other medical science, MESH: Social Behavior, medicine.medical_specialty, 03 medical and health sciences, MESH : HIV Infections, Humans, MESH : Middle Aged, Antiviral, Social Behavior, Pharmacology, MESH: Humans, MESH: Questionnaires, MESH : Humans, MESH : Follow-Up Studies, MESH: Adult, MESH : Proportional Hazards Models, medicine.disease, Antiretroviral agent, MESH: Female, Immune deficiency, MESH : Social Behavior, MESH : HIV, MESH: Proportional Hazards Models, Risk Factors, MESH : Depression, MESH: Risk Factors, MESH : Female, 030212 general & internal medicine, MESH: Longitudinal Studies, MESH : Longitudinal Studies, MESH : Suicide, Incidence (epidemiology), MESH : Questionnaires, Middle Aged, Viral Load, MESH : Adult, MESH : Risk Factors, AIDS, Treatment Outcome, Infectious Diseases, Female, France, MESH: Viral Load, Adult, MESH: Depression, MESH : Male, MESH : Treatment Outcome, Acquired immunodeficiency syndrome (AIDS), MESH : CD4 Lymphocyte Count, medicine, Chemotherapy, MESH : France, Psychiatry, Proportional Hazards Models, MESH: HIV Protease Inhibitors, 030505 public health, Potential risk, business.industry, MESH : Drug Therapy, Combination, HIV, HIV Protease Inhibitors, Antiretroviral therapy, MESH: Male, CD4 Lymphocyte Count, Treatment, MESH: France, MESH: Drug Therapy, Combination, MESH: Suicide, Predictive factor, business, Follow-Up Studies
Abstract

Background Psychiatric disorders are relatively common among HIV-infected patients. However, there are few studies about their potential risk factors. This analysis aimed to measure the incidence of severe psychiatric events (PE) among patients receiving combination antiretroviral therapy (cART) of the French APROCO-COPILOTE (ANRS CO8) cohort, and to identify the medical and socio-behavioural correlates of their first episode of depression, suicide or suicide attempt (D/S/SA). Methods APROCO-COPILOTE is a cohort of patients started on a protease inhibitor regimen between 1997 and 1999, with prospective medical standardized records and self-administered questionnaires collecting socio-demographic and socio-behavioural data. This analysis included all 11-year follow-up visits for 1,095 patients having completed baseline self-administered questionnaires. A proportional hazard Cox model was used to identify the correlates of a first D/S/SA event. Results The overall prevalence of severe PE remained low: 50 patients experienced 67 events (incidence rate [95% CI] =1.04 [0.82, 1.32] per 100 person-years). Depression ( n=16), suicides ( n=5) and suicide attempts ( n=14) were the most frequently diagnosed PE (0.54 [0.39, 0.76] per 100 person-years) among 25 patients. Multivariate results showed that unemployment, unstable housing, detectable viral load and smoking more than 20 cigarettes/day were independently associated with D/S/SA. Conclusions Although the incidence of severe PE remained relatively low among the patients of APROCO-COPILOTE cohort, this study's results underline a clinically important problem in HIV-infected patients receiving cART. Furthermore, our findings not only emphasize the importance of comprehensive care, especially for socially vulnerable patients, but may also help future studies designed to assess the effectiveness of interventions in reducing the risk of PE during cART.

Published
2012

2. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients

Author

Bouillon-Pichault, Marion, primary, Jullien, Vincent, additional, Piketty, Christophe, additional, Viard, Jean-Paul, additional, Morini, Jean-Pierre, additional, Chhun, Stéphanie, additional, Krivine, Anne, additional, Salmon, Dominique, additional, Dupin, Nicolas, additional, Weiss, Laurence, additional, Lortholary, Olivier, additional, Pons, Gérard, additional, Launay, Odile, additional, and Treluyer, Jean-Marc, additional

Published
2009
Full Text
View/download PDF

3. Antiretroviral Therapy and Sustained Virological Response to HCV Therapy are Associated with Slower Liver Fibrosis Progression in HIV–HCV-Coinfected Patients: Study from the Anrs Co 13 Hepavih Cohort

Author

Loko, Marc-Arthur, Bani-Sadr, Firouze, Valantin, Marc-Antoine, Lascoux-Combe, Caroline, Fontaine, Hélène, Bonnard, Philippe, Gervais, Anne, Bouchaud, Olivier, Garipuy, Daniel, Quertainmont, Yann, Vittecoq, Daniel, Tehrani, Michka Shoai, Winnock, Maria, Dabis, François, and Salmon, Dominique

Abstract

Background The aim of this study was to describe changes in repeated liver stiffness (LS) measurements and to assess the determinants of increase in LS in HIV– HCV-coinfected patients.Methods HIV–HCV-coinfected adults enrolled in the ANRS CO 13 HEPAVIH cohort, for whom two results of LS, evaluated over ≥24 months, were available. Patients with unreliable LS results were not included. LS was measured at baseline and every year thereafter. Determinants of LS increase were assessed using linear (primary outcome: last LS minus first LS value) and logistic (secondary outcome: ≥30% increase in the initial LS value) regression analyses.Results A total of 313 patients (mean age 45 years, 67.4% male) were included. Overall, 93.9% were receiving antiretroviral treatment (ART). The mean baseline CD4+T-cell count was 471 cells/mm3and 72.2% of patients had undetectable plasma HIV RNA. The mean interval between the first and last LS measurements was 33.5 months. No significant difference was found between baseline and follow-up mean LS values (P=0.39). However, a decrease of ≥30% in LS was observed in 48 (15.3%) patients and an increase of ≥30% in 64 (20.5%) patients. In multivariate linear and logistic analyses, excessive alcohol intake (P coefficient 6.8; P=0.0006) and high HCV viral load (OR 1.7, 95% CI 1.1, 2.5; P=0.01) were independently associated with an increase in LS, whereas time on ART>114.5 months (OR 0.5, 95% CI 0.3, 0.9; P=0.03) and achievement of sustained virological response (OR 0.1, 95% CI 0.01, 0.9; P=0.04) were independently associated with no increase in LS.Conclusions Our findings show that long-term ART and achieving sustained virological response in HIV-HCV-coinfected patients are both significantly associated with lack of increase in LS over a 33-month period.

Published
2012
Full Text
View/download PDF

4. Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals

Author

Costagliola, Dominique, Potard, Valérie, Duvivier, Claudine, Pradier, Christian, Dupont, Caroline, Salmon, Dominique, Duval, Xavier, Billaud, E, Boué, F, Costagliola, D, Duval, X, Duvivier, C, Enel, P, Fournier, S, Gasnault, J, Gaud, C, Gilquin, J, Grabar, S, Khuong, MA, Lang, JM, Mary-Krause, M, Matheron, S, Meyohas, MC, Pialoux, G, Poizot-Martin, I, Pradier, C, Rouveix, E, Salmon-Ceron, D, Sobel, A, Tattevin, P, Tissot-Dupont, H, Yasdanpanah, Y, Aronica, E, Tirard-Fleury, V, Tortay, I, Abgrall, S, Costagliola, D, Grabar, S, Guiguet, M, Lanoy, E, Leneman, H, Lièvre, L, Mary-Krause, M, Potard, V, Saidi, S, Matheron, S, Vildé, JL, Leport, C, Yeni, P, Bouvet, E, Gaudebout, C, Crickx, B, Picard-Dahan, C, Weiss, L, Tisne-Dessus, D, Tarnier-Cochin, GH, Sicard, D, Salmon, D, Gilquin, J, Auperin, I, Viard, JP, Roudière, L, Boué, F, Fior, R, Delfraissy, JF, Goujard, C, Lesprit, Ph, Jung, C, Meyohas, MC, Meynard, JL, Picard, O, Desplanque, N, Cadranel, J, Mayaud, C, Pialoux, JF, Rozenbaum, W, Bricaire, F, Katlama, C, Herson, S, Simon, A, Decazes, JM, Molina, JM, Clauvel, JF, Gerard, L, Widal, GH Lariboisière-Fernand, Sellier, P, Diemer, M, Dupont, C, Berthé, H, Saïag, P, Mortier, E, Chandemerle, C, de Truchis, P, Bentata, M, Honoré, P, Tassi, S, Jeantils, V, Mechali, D, Taverne, B, Laurichesse, H, Gourdon, F, Lucht, JF, Fresard, A, de Dijon, Chru, de Belfort, CH, Faller, JP, Eglinger, P, Bazin, C, Verdon, R, de Grenoble, Cisih, de Lyon, Cisih, Peyramond, D, Boibieux, A, Touraine, JL, Livrozet, JM, Trepo, C, Cotte, L, Ravaux, I, Tissot-Dupont, H, Delmont, JP, Moreau, J, Gastaut, JA, Poizot-Martin, I, Soubeyrand, J, Retornaz, F, Blanc, PA, Allegre, T, Galinier, A, Ruiz, JM, d'Arles, CH, d'Avignon, CH, Lepeu, G, Granet-Brunello, P, Pelissier, L, Esterni, JP, de Martigues, CH, Nezri, M, Cohen-Valensi, R, Laffeuillade, A, Chadapaud, S, de Nîmes, J Reynes; CHG, May, T, Rabaud, C, Raffi, F, Billaud, E, Pradier, C, Pugliese, P, Michelet, C, Arvieux, C, Caron, F, Borsa-Lebas, F, Lang, JM, Rey, D, de Mulhouse, P Fraisse; CH, Massip, P, Cuzin, L, Arlet-Suau, E, Legrand, MF Thiercelin, Rangueil, CHU, de Tourcoing, CH, Yasdanpanah, Y, Sobesky, M, Pradinaud, R, Gaud, C, and Contant, M

Abstract

Objective To study the prognosis of HIV-infected patients with virological failure after exposure to three classes of antiretroviral drugs (ARVs).Design Cohort study. Setting: French Hospital Database on HIV.Patients Patients previously exposed to at least two nucleoside reverse transcriptase inhibitors (NRTIs), two protease inhibitors and one non-NRTI, with viral load (VL) values of >5000 copies/ml after the exposure criteria were met and a new treatment initiated between 1998 and 2001 with VL >5000 copies/ml.Main outcome measures Risk of new AIDS-defining-events (ADEs) or death from first introduction of a drug never used before occurring between 1998 and 2001 defined as baseline.Results The main baseline characteristics of the 1092 patients were: previous ADE in 49% of cases, median CD4 cell count 181 µl, median VL 4.9 log10copies/ml, median duration of ARV therapy 5.0 years and previous exposure to a median of nine ARVs. The crude progression rates were 20.1/100 patient-years among patients included in 1998, 15.1 in 1999, 11.1 in 2000 and 8.6 in 2001. After adjustment for baseline characteristics, the calendar year of inclusion was associated with the risk of clinical progression (P<0.001). When the types of newly available drugs used at baseline or during follow-up were introduced into the model, year of inclusion was no longer associated with the risk of clinical progression (P=0.42), while exposure to amprenavir/r, lopinavir/r, abacavir or tenofovir was associated with a lower risk.Conclusions The clinical prognosis of heavily pretreated patients experiencing virological failure improved between 1998 and 2001, mainly thanks to the use of newly available drugs with more favourable resistance profiles.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results